Knowledge Assessment: Types of Risk Management Plans

Only the product label and a summary of spontaneous adverse-event reports A safety specification, pharmacovigilance plan, risk minimisation measures, study commitments, and lifecycle management approach Only additional post-authorisation studies, without routine pharmacovigilance activities A global commercial strategy and country sales forecasts

A long-established generic with no formulation or device differences A new active substance with limited experience in special populations A generic that is identical in route and formulation to its reference product A mature product undergoing only a minor administrative variation

The commercial importance of the product determines how much documentation is required Risk management should be proportionate to the residual uncertainty and nature of the product All products must use the same RMP structure, but companies may choose different levels of detail The country of manufacture is the primary determinant of RMP content

Automatically copy the reference RMP without further assessment Treat the generic as requiring a full RMP in every case Assess and document excipient-specific uncertainties, such as hypersensitivity, and plan targeted monitoring if justified Exclude the excipient from the RMP because it is not an active substance

A scientific justification for extrapolation accompanied by surveillance appropriate to the indications concerned No additional safety analysis because extrapolation is based on similarity A plan limited to monitoring manufacturing costs A requirement to repeat every clinical trial conducted for the reference product

Replace the existing RMP automatically with a new full RMP Start from the reference RMP and assess whether the extension creates new concerns or materially changes exposure Remove all existing safety concerns because the extension is authorised separately Assess only the commercial impact of the new strength or route

A single commercial employee approving all RMP changes without cross-functional review Defined ownership, QPPV oversight, cross-functional review, documented approvals, and escalation for unresolved differences Local affiliates making safety decisions without reference to global governance Allowing RMP authors to approve their own changes without an audit trail

Monitoring only the generic name used in national formularies Immunogenicity and manufacturing-related differences that could affect safety or efficacy Replacing all reference-product safety data with in vitro testing Assessing only the product's marketing authorisation route

Generic products are exempt from pharmacovigilance obligations The reference product provides an extensive safety evidence base, allowing focus on whether the generic introduces product-specific uncertainties Abridged RMPs are used whenever a company has limited pharmacovigilance resources The generic's safety profile is assumed to be identical without any comparative assessment

The product is a novel therapy with conditional approval and several ongoing safety studies The product has been marketed for many years with no new data The company changes its internal document numbering convention A country changes its product logo without changing the product